Ballicules.com
REMS restricted

Ambrisentan

LETAIRIS

What it isSelective endothelin A receptor antagonist; pulmonary arterial hypertension.

Why this oneOnce daily, and combined with tadalafil up front it improves outcomes more than either alone.

What limits itEmbryo-fetal toxicity under a REMS. Peripheral edema and anemia; it is contraindicated in idiopathic pulmonary fibrosis.

FDA-approved for

FDA label

BOXED WARNING Embryo-fetal toxicity—may cause major birth defects; contraindicated in pregnancy. Exclude pregnancy before starting and use effective contraception during and for 1 month after treatment.
FDA dosingPopulationStartTargetMax
Pulmonary arterial hypertension (WHO Group 1)Adult5 mg QD5–10 mg QD10 mg QD

Titration May increase at 4-week intervals as needed and tolerated.

Renal No adjustment for mild–moderate impairment; no data in severe impairment.

Hepatic Not recommended in moderate or severe impairment; no data in mild.

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy Contraindicated—may cause fetal harm, including birth defects and fetal death (teratogenic in animals).

Lactation Unknown whether present in human milk; decide whether to discontinue breastfeeding or the drug.

⚠ BOXED WARNING

Cost, est. cash$10–$300/month

Generic entry2019

Classes and tags

Clinical profile

Therapeutic safety burden1 / 4
Overdose danger1 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk1 / 4

Legacy pregnancy categoryUnknown / historical label unavailable

Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.

Mechanism of action: Ambrisentan ballicule

Ambrisentan ballicule: receptor binding, kinetics and half-life diagram

Open Ambrisentan in the interactive console ↗